Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

Hologic, Inc. is a developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company"s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.
Website: hologic.com


  • Pretty weak financial results growth rate 3.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-2.1%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 2.4% (LTM)
  • Share price is 42.6% higher than minimum and 10.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (19.9x vs 19.9x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: HOLX
Share price, USD:  (0.0%)75.19
year average price 71.63  


year start price 62.57 2025-06-04

min close price 62.57 2025-06-04

max close price 75.19 2026-01-26

current price 75.19 2026-06-03
Common stocks: 224 405 000

Dividend Yield:  0.0%
FCF Yield LTM: 2.4%
EV / LTM EBITDA: 19.9x
EV / EBITDA annualized: 16.2x
Last revenue growth (y/y):  +2.5%
Last growth of EBITDA (y/y):  +4.0%
Historical revenue growth:  -1.7%
Historical growth of EBITDA:  -2.5%
EV / Sales: 4.1x
Margin (EBITDA LTM / Revenue): 20.8%

Target EV / EBITDA (hist percentile): 19.9x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 16 873
Net Debt ($m): 144
EV (Enterprise Value): 17 017
EBITDA LTM (млн $): 857
EV / LTM EBITDA: 19.9x
Price to Book: 3.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-02zacks.com

Hologic (HOLX) International Revenue Performance Explored

2026-01-30zacks.com

HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash

2026-01-22zacks.com

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2026-01-22zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2026-01-22zacks.com

Hologic Q1 Earnings Preview: How Should You Play the Stock Now?

2026-01-21zacks.com

Will Hologic (HOLX) Beat Estimates Again in Its Next Earnings Report?

2026-01-21zacks.com

Here's Why Hologic (HOLX) is a Strong Momentum Stock

2026-01-21zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2025-12-22zacks.com

HOLX vs. LH: Which MedTech Stock Is the Stronger Investment Now?

2025-12-17zacks.com

HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-27 2025-06-28 2024-09-30 2024-06-29 2024-03-30 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-30 2021-09-30
symbol HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737
filingDate 2025-11-18 2024-11-27 2023-11-21 2022-11-15 2021-11-16
acceptedDate 2025-11-18 16:07:56 2025-07-31 07:39:05 2024-11-27 07:24:17 2024-07-30 16:06:04 2024-05-03 07:45:49 2024-02-02 07:36:20 2023-11-21 08:17:06 2023-08-01 07:26:12 2023-05-02 07:52:08 2023-02-01 16:04:57 2022-11-15 08:26:06 2021-11-16 08:36:50
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 4 101M 1 024M 4 030M 1 011M 1 018M 1 013M 4 030M 984M 1 027M 1 074M 4 863M 5 632M
costOfRevenue 1 599M 447M 1 803M 443M 455M 446M 1 959M 617M 441M 456M 1 865M 1 837M
grossProfit 2 501M 577M 2 228M 568M 563M 568M 2 072M 368M 586M 618M 2 997M 3 796M
researchAndDevelopmentExpenses 248M 61M 273M 64M 75M 67M 294M 73M 74M 75M 283M 276M
generalAndAdministrativeExpenses 449M 99M 409M 94M 100M 112M 392M 90M 101M 109M 408M 433M
sellingAndMarketingExpenses 621M 152M 585M 146M 144M 149M 595M 150M 142M 164M 630M 561M
sellingGeneralAndAdministrativeExpenses 1 070M 251M 995M 240M 245M 261M 988M 240M 243M 272M 1 038M 994M
otherExpenses 469M 9M 78M 200 000 9M -9M 121M 6M 7M 8M 36M 45M
operatingExpenses 1 787M 322M 1 345M 304M 319M 341M 1 403M 320M 324M 354M 1 357M 1 316M
costAndExpenses 3 386M 769M 3 148M 748M 775M 786M 3 362M 937M 765M 811M 3 223M 3 152M
netInterestIncome 32M -13M 9M -82M -92M
interestIncome 74M 16M 109M 28M 24M 28M 121M 33M 32M 21M 13M 1M
interestExpense 43M 29M 122M 32M 32M 26M 111M 28M 27M 28M 95M 94M
depreciationAndAmortization 300M 70M 309M 72M 74M 88M 323M 81M 105M 92M 430M 407M
ebitda 1 024M 334M 1 296M 345M 317M 198M 1 111M 167M 377M 354M 2 113M 2 862M
ebit 724M 987M 787M 1 683M 2 455M
nonOperatingIncomeExcludingInterest -10M -105M -119M -43M 26M
operatingIncome 714M 255M 883M 264M 243M 198M 668M 1M 272M 262M 1 640M 2 480M
totalOtherIncomeExpensesNet -33M -20M -18M -23M -32M -7M 8M -41M 7M -23M -52M -119M
incomeBeforeTax 681M 235M 865M 241M 212M 191M 676M 12M 279M 239M 1 588M 2 361M
incomeTaxExpense 116M 40M 76M 46M 42M -55M 220M 53M 61M 52M 286M 491M
netIncomeFromContinuingOperations 566M 790M 456M 1 302M 1 870M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncome 566M 195M 790M 195M 170M 247M 456M -41M 219M 187M 1 302M 1 872M
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 566M 790M 456M 1 302M 1 872M
eps 2.5 0.87 3.35 0.83 0.72 1.03 1.85 -0.16 0.88 0.76 5.18 7.28
epsDiluted 2.49 3.32 1.83 5.13 7.21
weightedAverageShsOut 227M 224M 236M 235M 236M 239M 247M 247M 248M 247M 252M 257M
weightedAverageShsOutDil 228M 225M 238M 236M 238M 240M 249M 247M 250M 249M 254M 260M
fillingDate 2025-07-31 2024-07-30 2024-05-03 2024-02-02 2023-08-01 2023-05-02 2023-02-01
calendarYear 2025 2024 2024 2024 2023 2023 2023
grossProfitRatio 0.563 0.562 0.553 0.56 0.373 0.571 0.575
ebitdaratio 0.326 0.332 0.311 0.196 0.17 0.367 0.33
operatingIncomeRatio 0.249 0.261 0.239 0.196 0.001 0.265 0.244
incomeBeforeTaxRatio 0.23 0.238 0.208 0.189 0.012 0.272 0.223
netIncomeRatio 0.19 0.192 0.167 0.243 -0.041 0.213 0.174
epsdiluted 0.86 0.82 0.72 1.03 -0.16 0.87 0.75
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-27 2025-06-28 2024-09-30 2024-06-29 2024-03-30 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-30 2021-09-30
symbol HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737
filingDate 2025-11-18 2024-11-27 2023-11-21 2022-11-15 2021-11-16
acceptedDate 2025-11-18 16:07:56 2025-07-31 07:39:05 2024-11-27 07:24:17 2024-07-30 16:06:04 2024-05-03 07:45:49 2024-02-02 07:36:20 2023-11-21 08:17:06 2023-08-01 07:26:12 2023-05-02 07:52:08 2023-02-01 16:04:57 2022-11-15 08:26:06 2021-11-16 08:36:50
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 1 960M 1 735M 2 160M 2 439M 2 180M 1 932M 2 723M 2 765M 2 582M 2 441M 2 340M 1 170M
shortTermInvestments 243M 144M 173M 9M 8M 22M 0 0 0 0 0 0
cashAndShortTermInvestments 2 203M 1 879M 2 334M 2 439M 2 180M 1 932M 2 723M 2 765M 2 582M 2 441M 2 340M 1 170M
netReceivables 601M 609M 600M 629M 647M 671M 626M 687M 714M 674M 618M 943M
accountsReceivables 601M 600M 626M 618M 943M
otherReceivables 0 0 0 0 0
inventory 679M 714M 680M 666M 649M 634M 618M 680M 688M 678M 624M 501M
prepaids 33M 53M 32M 49M 26M
otherCurrentAssets 152M 219M 156M 369M 312M 156M 187M 207M 228M 228M 232M 529M
totalCurrentAssets 3 668M 3 421M 3 823M 3 997M 3 789M 3 494M 4 185M 4 339M 4 211M 4 021M 3 862M 3 169M
propertyPlantEquipmentNet 654M 571M 630M 529M 525M 527M 580M 493M 498M 494M 551M 648M
goodwill 3 641M 3 644M 3 443M 3 291M 3 292M 3 306M 3 281M 3 298M 3 297M 3 290M 3 237M 3 282M
intangibleAssets 589M 642M 845M 688M 752M 833M 889M 940M 1 202M 1 255M 1 281M 1 659M
goodwillAndIntangibleAssets 4 230M 4 286M 4 288M 3 979M 4 044M 4 139M 4 170M 4 238M 4 499M 4 545M 4 517M 4 941M
longTermInvestments 79M 0 151M 6M 6M -20M 16M -19M 0 0 6M 10M
taxAssets 240M 0 129M 18M 18M 20M 57M 19M 33M 72M 16M 22M
otherNonCurrentAssets 145M 528M 136M 362M 332M 310M 133M 267M 207M 158M 120M 131M
totalNonCurrentAssets 5 347M 5 385M 5 333M 4 893M 4 926M 4 975M 4 955M 4 999M 5 237M 5 269M 5 209M 5 751M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 9 015M 8 806M 9 156M 8 890M 8 714M 8 470M 9 139M 9 338M 9 449M 9 290M 9 071M 8 920M
totalPayables 266M 273M 238M 242M 287M
accountPayables 193M 193M 204M 202M 203M 184M 175M 181M 187M 202M 198M 216M
otherPayables 73M 69M 62M 44M 71M
accruedExpenses 184M 197M 172M 176M 185M
shortTermDebt 3M 7M 38M 44M 41M 41M 287M 32M 26M 21M 15M 313M
capitalLeaseObligationsCurrent 31M 27M 24M 26M 31M
taxPayables 0 0 69M 106M 147M 102M 62M 34M 41M 31M 44M 71M
deferredRevenue 200M 213M 213M 219M 208M 191M 199M 233M 231M 192M 187M 198M
otherCurrentLiabilities 294M 550M 289M 429M 504M 484M 288M 536M 511M 542M 292M 314M
totalCurrentLiabilities 977M 963M 1 037M 1 002M 955M 899M 1 207M 981M 955M 956M 938M 1 327M
longTermDebt 2 505M 2 519M 2 497M 2 519M 2 514M 2 537M 2 531M 2 789M 2 798M 2 806M 2 808M 2 712M
capitalLeaseObligationsNonCurrent 88M 96M 62M 72M 89M
deferredRevenueNonCurrent 12M 12M 14M 15M 15M 14M 14M 14M 13M 11M 9M 20M
deferredTaxLiabilitiesNonCurrent 374M 47M 371M 18M 18M 20M 295M 19M 33M 72M 342M 461M
otherNonCurrentLiabilities 10M 423M 11M 386M 368M 345M 13M 352M 349M 353M 25M 93M
totalNonCurrentLiabilities 2 990M 3 001M 2 989M 2 937M 2 915M 2 917M 2 915M 3 175M 3 193M 3 242M 3 257M 3 375M
otherLiabilities 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 119M 14M 123M 16M 14M 18M 86M 19M 20M 21M 98M 119M
totalLiabilities 3 967M 3 964M 4 026M 3 939M 3 870M 3 816M 4 122M 4 156M 4 148M 4 198M 4 195M 4 701M
treasuryStock -4 611M -3 852M -3 036M -2 532M -1 989M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M
retainedEarnings 3 412M 3 224M 2 846M 2 667M 2 473M 2 303M 2 056M 1 966M 2 006M 1 788M 1 600M 298M
additionalPaidInCapital 6 345M 6 244M 6 141M 6 043M 5 966M
accumulatedOtherComprehensiveIncomeLoss -101M -90M -112M -140M -137M -119M -148M -114M -118M -127M -238M -59M
otherTotalStockholdersEquity 0 0 0 0 0
totalStockholdersEquity 5 048M 4 843M 5 130M 4 951M 4 844M 4 654M 5 017M 5 182M 5 301M 5 093M 4 876M 4 219M
totalEquity 5 048M 4 843M 5 130M 4 951M 4 844M 4 654M 5 017M 5 182M 5 301M 5 093M 4 876M 4 219M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9 015M 8 806M 9 156M 8 890M 8 714M 8 470M 9 139M 9 338M 9 449M 9 290M 9 071M 8 920M
totalInvestments 322M 144M 324M 6M 6M 2M 16M -19M 0 0 6M 10M
totalDebt 2 627M 2 523M 2 658M 2 559M 2 569M 2 578M 2 904M 2 821M 2 824M 2 827M 2 922M 3 145M
netDebt 667M 787M 498M 120M 389M 646M 182M 56M 242M 386M 582M 1 974M
fillingDate 2025-07-31 2024-07-30 2024-05-03 2024-02-02 2023-08-01 2023-05-02 2023-02-01
calendarYear 2025 2024 2024 2024 2023 2023 2023
othertotalStockholdersEquity 1 705M 2 420M 2 506M 2 467M 3 327M 3 410M 3 429M
totalLiabilitiesAndStockholdersEquity 8 806M 8 890M 8 714M 8 470M 9 338M 9 449M 9 290M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-27 2025-06-28 2025-03-29 2024-09-30 2024-06-29 2024-03-30 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-30 2021-09-30
symbol HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX HOLX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737 859 737
filingDate 2025-11-18 2024-11-27 2023-11-21 2022-11-15 2021-11-16
acceptedDate 2025-11-18 16:07:56 2025-07-31 07:39:05 2025-05-02 08:05:04 2024-11-27 07:24:17 2024-07-30 16:06:04 2024-05-03 07:45:49 2024-02-02 07:36:20 2023-11-21 08:17:06 2023-08-01 07:26:12 2023-05-02 07:52:08 2023-02-01 16:04:57 2022-11-15 08:26:06 2021-11-16 08:36:50
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome 566M 195M -17M 790M 195M 170M 247M 456M -41M 219M 187M 1 302M 1 872M
depreciationAndAmortization 300M 70M 76M 309M 72M 74M 88M 323M 81M 81M 86M 430M 407M
deferredIncomeTax -142M -29M 0 -72M -6M -29M -18M 0 -39M -35M -26M -166M 0
stockBasedCompensation 84M 14M 28M 82M 15M 26M 29M 80M 17M 23M 21M 67M 65M
changeInWorkingCapital -20M 80M -53M 84M 107M 28M -158M 3M 89M -69M -43M 454M -34M
accountsReceivables 8M 49M -4M 41M 18M 18M -38M -2M 31M -37M -45M 272M 111M
inventory -1M 7M -6M -47M -17M -17M -13M -5M 8M -9M -47M -137M -84M
accountsPayables -11M -18M 0 22M -200 000 20M 7M 0 -7M -15M 2M -14M 0
otherWorkingCapital -16M 42M -44M 68M 106M 8M -114M 9M 58M -8M 47M 333M -61M
otherNonCashItems 269M 14M 135M 92M 182M 177M 32M 189M 225M -12M 29M 39M 21M
netCashProvidedByOperatingActivities 1 057M 343M 169M 1 285M 406M 292M 220M 1 051M 333M 206M 253M 2 126M 2 330M
investmentsInPropertyPlantAndEquipment -78M -13M -40M -72M -44M -28M -38M -150M -37M -32M -29M -127M -178M
acquisitionsNet -322M 1M -323M -297M -43M 0 -31M -5M -12M 0 0 -159M -1 165M
purchasesOfInvestments -182M 0 0 -268M -3M -5M -35M 0 0 0 -10M 0 0
salesMaturitiesOfInvestments 176M 48M 0 0 0 0 -23M 0 0 0 0 0 0
otherInvestingActivities -77M -144M 3M 80M 13M
netCashProvidedByInvestingActivities -483M -781M -152M -206M -1 330M
netDebtIssuance -40M -291M -19M -212M -112M
longTermNetDebtIssuance -40M -291M -19M -212M -112M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -714M -797M -499M -542M -457M
netCommonStockIssuance -714M -797M -499M -542M -457M
commonStockIssuance 39M 38M 0 0 0
commonStockRepurchased -753M -36M -200M -835M -100M -100 000 -677M -499M -114M -50M -100M -542M -457M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -23M -20M 35M -2M 39M
netCashProvidedByFinancingActivities -777M -1 109M -483M -756M -530M
effectOfForexChangesOnCash 2M 7M 4M 9M -300 000 -2M 4M 300 000 -2M 500 000 3M 6M -2M
netChangeInCash -201M 306M -353M -596M 259M 248M -824M 416M 183M 141M 102M 1 169M 469M
cashAtEndOfPeriod 1 960M 1 735M 1 430M 2 160M 2 439M 2 180M 1 932M 2 756M 2 765M 2 582M 2 441M 2 340M 1 170M
cashAtBeginningOfPeriod 2 160M 1 430M 1 782M 2 756M 2 180M 1 932M 2 756M 2 340M 2 582M 2 441M 2 340M 1 170M 701M
operatingCashFlow 1 057M 343M 169M 1 285M 406M 292M 220M 1 051M 333M 206M 253M 2 126M 2 330M
capitalExpenditure -137M -13M -40M -140M -44M -28M -38M -150M -37M -32M -29M -127M -178M
freeCashFlow 920M 331M 129M 1 145M 362M 264M 182M 901M 296M 174M 224M 1 999M 2 153M
incomeTaxesPaid 0 138M 0 36M 0
interestPaid 0 0 105M 100M 93M
fillingDate 2025-07-31 2025-05-02 2024-07-30 2024-05-03 2024-02-02 2023-08-01 2023-05-02 2023-02-01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
otherInvestingActivites -41M 38M 4M -6M 22M 10M 16M -2M
netCashUsedForInvestingActivites -4M -324M -43M -39M -104M -39M -16M -41M
debtRepayment -10M -10M -10M -10M -260M -5M -5M -5M
commonStockIssued 7M 0 0 9M 10M 0 0 15M
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites -1M 9M 7M -3M -16M 9M 6M -24M
netCashUsedProvidedByFinancingActivities -40M -202M -104M -4M -944M -110M -50M -114M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2025 q2
2025-07-30 ET (fiscal 2025 q3)
2025 q1
2025-05-01 ET (fiscal 2025 q2)
2024 q4
2025-02-05 ET (fiscal 2025 q1)
2024 q3
2024-11-04 ET (fiscal 2024 q4)
2024 q2
2024-07-29 ET (fiscal 2024 q3)
2024 q1
2024-05-02 ET (fiscal 2024 q2)
2023 q4
2024-02-01 ET (fiscal 2024 q1)
2023 q3
2023-11-09 ET (fiscal 2023 q4)
2023 q2
2023-07-31 ET (fiscal 2023 q3)
2023 q1
2023-05-01 ET (fiscal 2023 q2)
2022 q4
2023-02-01 ET (fiscal 2023 q1)
2022 q3
2022-10-31 ET (fiscal 2022 q4)
2022 q2
2022-07-27 ET (fiscal 2022 q3)
2022 q1
2022-04-27 ET (fiscal 2022 q2)
2021 q4
2022-02-02 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-01-29 21:02 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2026
2026-01-15 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
2026-01-13 ET
Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening
2025-12-16 ET
Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams
2025-12-02 ET
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
2025-11-25 ET
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA
2025-11-12 ET
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
2025-11-03 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025
2025-10-29 ET
HOLX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Hologic to Blackstone and TPG
2025-10-21 ET
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share
2025-10-02 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025
2025-10-02 ET
Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis
2025-09-30 ET
New Survey Results Underscore the Need to #BustTheMyth About Mammograms
2025-09-29 ET
Volition Signs Co-Marketing and Services Agreement with Hologic
2025-09-29 ET
Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm
2025-09-26 ET
New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at EUSOBI
2025-09-03 ET
Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
2025-07-30 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2025
2025-07-02 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
2025-05-22 ET
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
2025-05-13 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2025-05-01 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2025
2025-04-24 ET
Groundbreaking New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at SBI
2025-04-22 ET
Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report
2025-04-04 ET
Wayde McMillan Elected to Hologic Board of Directors
2025-04-03 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025
2025-02-25 ET
Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference
2025-02-20 ET
Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
2025-02-18 ET
Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay
2025-02-05 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2025
2025-01-21 ET
New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide
2025-01-12 ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025
2025-01-07 ET
Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-06 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025
2025-01-06 ET
Hologic Completes Acquisition of Gynesonics, Inc.
2024-12-18 ET
Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC
2024-12-10 ET
Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines
2024-12-09 ET
Martin Madaus Elected to Hologic Board of Directors
2024-12-09 ET
New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence
2024-12-02 ET
Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations
2024-11-25 ET
Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024
2024-11-14 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2024-11-04 21:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024
2024-10-14 12:05 ET
Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women’s Health
2024-10-04 12:22 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024
2024-09-30 13:17 ET
Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month
2024-08-29 12:08 ET
Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference    
2024-07-29 20:01 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2024
2024-07-25 12:19 ET
Hologic Completes Acquisition of Endomagnetics Ltd
2024-07-12 13:00 ET
Attorney Moze Cowper Wins Oral Argument Against Hologic Inc. in BioZorb Litigation
2024-07-09 08:05 ET
72 Million American Women Have Skipped or Delayed Vital Screenings
2024-07-02 12:22 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024
2024-05-21 12:08 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2024-05-02 20:01 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2024
2024-04-29 20:05 ET
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company
2024-04-11 18:07 ET
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
2024-04-02 12:08 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
2024-03-05 13:10 ET
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
2024-02-27 13:00 ET
Hologic to Unveil Groundbreaking AI Research at ECR 2024
2024-02-26 21:15 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2024-02-01 22:35 ET
Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System
2024-02-01 21:01 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2024
2024-01-16 13:30 ET
Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
2024-01-11 13:08 ET
Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women
2024-01-07 21:00 ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024
2024-01-04 13:33 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2024 on Thursday, February 1, 2024
2024-01-02 13:08 ET
Hologic to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-30 11:00 ET
KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation
2023-11-24 13:05 ET
Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023
2023-11-21 13:15 ET
Hologic to Webcast Presentation at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 21:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023
2023-11-02 17:15 ET
MedTech Industry Leader Ian Heynen Commences CEO Role at NuGen
2023-10-12 11:00 ET
NuGen Medical Appoints Industry Leader Ian Heynen as CEO
2023-10-10 12:30 ET
Hologic Announces Innovative Collaboration with AAGL and Inovus Medical to Optimize OB-GYN Training for Minimally Invasive Surgeries
2023-10-05 12:00 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2023 on Thursday, November 9, 2023
2023-09-29 12:00 ET
Hologic to Expand Outreach During Breast Cancer Awareness Month
2023-09-22 12:00 ET
Nanaz Mohtashami Elected to Hologic Board of Directors
2023-09-21 12:30 ET
Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities
2023-08-30 12:00 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2023-07-31 20:01 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2023
2023-07-05 12:08 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023
2023-05-19 12:08 ET
Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
2023-05-16 13:12 ET
Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family
2023-05-08 12:00 ET
Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family
2023-05-02 20:02 ET
Hologic to Webcast Presentation at the BofA Securities 2023 Healthcare Conference
2023-05-01 20:02 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2023
2023-04-03 20:04 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2023 on Monday, May 1, 2023
2023-02-28 13:08 ET
Hologic to Webcast Presentation at the Cowen 43rd Annual Health Care Conference
2023-02-21 21:02 ET
Hologic “Making a World of Difference” Through Global Sustainability Impact
2023-02-17 13:08 ET
Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent
2023-02-15 13:00 ET
NovaSure® V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe
2023-02-01 21:01 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2023
2023-01-08 21:00 ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023
2023-01-03 13:08 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2023 on Wednesday, February 1, 2023
2022-12-27 21:02 ET
Hologic to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-09 21:15 ET
Stacey D. Stewart Elected to Hologic Board of Directors
2022-12-06 21:04 ET
New Data Presented at SABCS 2022 Reveal Expanded Predictive Value of the Breast Cancer Index™ Test for Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
2022-12-01 13:05 ET
Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
2022-11-25 13:08 ET
Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
2022-11-22 13:22 ET
Hologic to Webcast Presentation at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-03 12:00 ET
Hologic’s 3Dimensions™ System for 3D Mammography Receives EUREF Type Test Certification
2022-11-02 12:02 ET
Hologic Announces Contract with BARDA to Support IVD Approval of COVID Assays
2022-10-31 20:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022
2022-10-04 12:22 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2022 on Monday, October 31, 2022
2022-10-03 12:00 ET
Hologic Rings Nasdaq Opening Bell to Kick Off Breast Cancer Awareness Month
2022-09-21 11:00 ET
More than 1.5 Billion Women Worldwide Lack Essential Health Screenings
2022-08-30 12:08 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2022-08-12 12:01 ET
Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care
2022-08-11 22:06 ET
U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights
2022-08-01 03:30 ET
Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
2022-07-27 20:02 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2022
2022-07-13 12:00 ET
Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022
2022-07-11 12:00 ET
Hologic Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV
2022-07-05 20:04 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022
2022-07-01 12:05 ET
New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options
2022-05-25 12:02 ET
Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients
2022-05-17 12:15 ET
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
2022-05-10 20:02 ET
Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
2022-05-04 12:30 ET
Hologic to Webcast Presentation at Upcoming Investor Conference
2022-04-27 20:01 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
2022-04-25 12:08 ET
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy
2022-04-04 20:01 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022
2022-03-24 12:00 ET
Hologic Opens New Innovation Center in France
2022-03-09 13:00 ET
Hologic WTA Tour Swings into Action Ahead of BNP Paribas Open
2022-03-03 12:00 ET
Hologic Partners With the WTA Tour in Landmark Title Sponsorship
2022-02-15 21:05 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2022-02-02 21:01 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2022
2022-02-01 12:00 ET
Hologic Launches First-Ever National Advertising Campaign Featuring Mary J. Blige
2022-01-24 13:08 ET
Hologic’s Sustainability Leadership Makes Company “A Global Force for Good”
2022-01-09 21:00 ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022
2022-01-05 21:05 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2022 on Wednesday, February 2, 2022
2022-01-05 13:00 ET
Hologic Adds Aptima SARS-CoV-2 Assay to its Global Access Initiative in Resource-Limited Countries
2021-12-28 13:15 ET
Hologic to Webcast Presentation at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-23 13:08 ET
Hologic Launches Panther Trax for High Volume Molecular Testing
2021-12-10 13:05 ET
Hologic Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation
2021-11-30 14:00 ET
Hologic Closes on Acquisition of Bolder Surgical
2021-11-30 13:02 ET
Hologic Pledges to Donate $5 Million to Improve Women’s Health, STEM Education and Social Justice
2021-11-30 01:26 ET
Hologic’s COVID-19 Tests Detect Omicron Variant
2021-11-23 13:05 ET
Hologic to Host Innovative Product Experiences and Medical Education Sessions On-site and Virtually at RSNA 2021
2021-11-22 21:04 ET
Hologic to Webcast Presentation at Upcoming Virtual Investor Conference
2021-11-04 08:00 ET
Hologic Announces European Launch of Genius™ Digital Diagnostics System for Cervical Cancer Screening
2021-11-02 12:08 ET
Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists 50th Global Congress
2021-11-01 20:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021
2021-10-27 20:02 ET
Hologic’s Multiplex COVID-19/Flu Test Now Commercially Available in North America and Europe
2021-10-20 12:15 ET
Hologic Debuts Documentary-Style Film Highlighting One Woman's Breast Cancer Journey Timed to Breast Reconstruction Awareness Day
2021-10-19 12:00 ET
Experts Issue a Call-to-Action to Recognize Periods as a Vital Sign of Health to Reduce Disparities in Uterine Fibroid Care for Black Women
2021-10-14 20:02 ET
Hologic to Acquire Bolder Surgical for $160 Million, Expanding its Surgical Franchise
2021-10-07 20:05 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2021 on Monday, November 1, 2021
2021-10-05 07:00 ET
Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe
2021-10-04 10:00 ET
Hologic Rings Nasdaq Opening Bell for 15th Time to Kick Off Breast Cancer Awareness Month
2021-09-30 12:00 ET
Hologic Expands its Omni® Hysteroscopy Offering in Europe
2021-09-28 12:33 ET
R2 Technologies’ Novel Glacial Rx® System Earns Third FDA Indication and Unique Product Code
2021-09-21 11:00 ET
Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls
2021-09-02 20:04 ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
2021-08-23 12:05 ET
Anthem, Nation’s Second Largest Health Plan, Now Covers Hologic’s Acessa Procedure as a Treatment for Uterine Fibroids
2021-07-28 20:01 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2021
2021-07-26 12:02 ET
New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium
2021-07-21 12:00 ET
R2 Technologies Receives Series C Investment to Fuel Business Growth, Expand Corporate Footprint and Tap into the Global Market
2021-07-14 06:00 ET
Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test
2021-07-06 12:15 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2021 on Wednesday, July 28, 2021
2021-06-23 06:45 ET
Hologic Receives European CE Mark for Molecular Assay to Quantify Human Cytomegalovirus
2021-06-17 12:45 ET
Hologic Completes Acquisition of Mobidiag
2021-06-03 20:27 ET
Cigna Updates Medical Policy to Cover Hologic’s Acessa® Procedure, Expanding Access to Millions of Women Across the Country
2021-05-24 12:24 ET
New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Minimally Invasive, Uterine Preserving Treatment Option
2021-05-11 12:03 ET
Hologic and Partners Launch Project Health Equality to Help Transform the Care Women of Color Receive in the Health Care System
2021-05-10 20:02 ET
Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer
2021-05-04 23:09 ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
2021-04-28 20:01 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2021
2021-04-08 12:00 ET
Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million
2021-04-07 12:17 ET
R2 Technologies Disrupts the Aesthetics Industry with Its Groundbreaking Glacial Rx™ Treatment
2021-04-07 12:08 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021
2021-03-22 12:03 ET
Hologic Receives Gallup Exceptional Workplace Award
2021-03-08 13:01 ET
Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide
2021-03-01 12:00 ET
Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million
2021-02-22 21:02 ET
Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market
2021-02-19 10:30 ET
New Research Published in the Journal of the American College of Radiology Confirms Black Women More Likely to Receive Inferior Breast Cancer Screening Than White Women, Points to Need for Stronger Breast Health Equity Reform
2021-02-11 13:00 ET
AMETEK Announces Appointment of Karleen Oberton to Board of Directors
2021-02-10 21:05 ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
2021-02-04 13:08 ET
Hologic’s New Sustainability Report Highlights How the Company’s Purpose-Driven Culture is Making a Unique Difference in the World
2021-02-01 21:01 ET
Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities
2021-01-27 21:01 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2021
2021-01-08 14:00 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021
2021-01-08 13:30 ET
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021
2021-01-05 21:01 ET
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million
2021-01-04 13:05 ET
Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million
2020-12-28 21:02 ET
Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-17 17:00 ET
Hologic Adds 3D Breast Ultrasound Imaging to SuperSonic™ MACH™ 40 System
2020-12-01 13:05 ET
Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection
2020-11-27 13:08 ET
Hologic to Showcase Products Across Breast Cancer Screening, Biopsy, Surgery and Treatment at Virtual RSNA 2020
2020-11-25 13:30 ET
Hologic to Webcast Presentation at Upcoming Virtual Investor Conference
2020-11-20 13:08 ET
Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection
2020-11-17 07:00 ET
Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening
2020-11-04 21:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020
2020-10-30 21:56 ET
Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity
2020-10-26 12:00 ET
Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe
2020-10-07 20:04 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020
2020-10-06 20:03 ET
FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling
2020-10-01 20:02 ET
Hologic Announces Multi-Year, Multi-Pronged Commitment to Tackling Breast Cancer Screening Disparities for Black Women in Partnership with the Black Women’s Health Imperative and RAD-AID
2020-09-28 12:00 ET
Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay
2020-09-14 22:52 ET
Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029
2020-09-14 12:01 ET
Hologic Announces Offering of $950 Million of Senior Notes Due 2029
2020-09-04 20:02 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2020-08-25 20:02 ET
Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids
2020-08-11 12:02 ET
Hologic Launches Validated Pooling Protocol for COVID-19 Testing
2020-08-03 12:08 ET
Hologic Announces ‘Back to Screening’ Campaign Encouraging Women to Prioritize Mammograms Delayed due to COVID-19 Pandemic
2020-07-31 12:00 ET
New Cervical Cancer Screening Guidelines from the American Cancer Society Risk Reversing Decades of Progress Made Against Cervical Cancer
2020-07-29 20:01 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2020
2020-07-10 17:01 ET
Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40
2020-07-08 12:08 ET
Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40
2020-07-02 12:15 ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2020 on Wednesday, July 29, 2020
2020-06-01 20:05 ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
2020-05-15 12:01 ET
Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19
2020-05-06 12:15 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2020-04-29 20:01 ET
Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)
2020-04-29 20:01 ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2020
2020-04-07 12:05 ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2020 on Wednesday, April 29, 2020
2020-04-07 11:30 ET
Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic
2020-03-16 23:54 ET
Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization
2020-03-05 07:00 ET
German Lab Demonstrates Feasibility to Detect SARS-Coronavirus-2 (SARS-CoV-2) Using Hologic’s Panther Fusion® System
2020-02-18 22:02 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2020-02-05 13:08 ET
Hologic Launches New Scalable Options for Panther System in the United States and Europe
2020-01-29 21:02 ET
Hologic Announces Financial Results for First Quarter of Fiscal 2020
2020-01-22 21:05 ET
Hologic’s First Sustainability Report Highlights Global Corporate Citizenship Efforts in Fiscal 2019
2020-01-12 22:00 ET
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020
2020-01-07 13:22 ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
2019-12-31 13:30 ET
Hologic to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-30 14:24 ET
Hologic Completes Divestiture of Cynosure Medical Aesthetics Business
2019-12-02 12:00 ET
Women’s Healthcare Leader Hologic to Showcase Comprehensive Portfolio of Breast and Skeletal Health Solutions at RSNA 2019
2019-11-27 13:22 ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
2019-11-25 13:22 ET
Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods
2019-11-20 12:30 ET
Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & Rice
2019-11-20 12:30 ET
Clayton, Dubilier & Rice to Acquire Market-Leading Medical Aesthetics Technology Company
2019-11-12 13:15 ET
Hologic Announces FDA Approval of 3DQuorum™ Imaging Technology, Powered by Genius AI™
2019-11-11 13:10 ET
Newly Published Research Demonstrates Ability of Hologic’s Assay to Detect Mycoplasma Genitalium, “the Silent Epidemic”
2019-11-06 21:01 ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2019
2019-10-29 07:00 ET
Cynosure Extends Body Contouring Portfolio with Launch of StimSure® in Europe
2019-10-24 20:21 ET
USA Today Article Confuses Patients on Benefits of 3D Mammography for Breast Cancer Screening
2019-10-14 14:13 ET
No More Excuses: There is Now a More Comfortable Mammogram
2019-10-10 20:05 ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2019 on Wednesday, November 6, 2019
2019-10-01 12:08 ET
Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2
2019-07-31 20:01 ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2019

SEC forms

Show financial reports only

SEC form 10
2026-01-29 16:08 ET
Hologic reported for 2025 q4
SEC form 8
2026-01-29 16:02 ET
Hologic published news for 2025 q4
SEC form 8
2026-01-29 16:02 ET
Hologic reported for 2025 q4
SEC form 8
2025-11-03 16:01 ET
Hologic published news for 2025 q3
SEC form 8
2025-11-03 16:01 ET
Hologic reported for 2025 q3
SEC form 10
2025-07-31 11:39 ET
Hologic published news for 2025 q2
SEC form 8
2025-07-30 20:01 ET
Hologic published news for 2025 q2
SEC form 8
2025-07-30 20:01 ET
Hologic reported for 2025 q2
SEC form 10
2025-05-02 00:00 ET
Hologic published news for 2025 q1
SEC form 8
2025-05-01 20:02 ET
Hologic published news for 2025 q1
SEC form 8
2025-05-01 20:02 ET
Hologic reported for 2025 q1
SEC form 10
2025-02-06 00:00 ET
Hologic reported for 2024 q4
SEC form 8
2025-02-05 00:00 ET
Hologic published news for 2024 q4
SEC form 8
2025-02-05 00:00 ET
Hologic reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Hologic published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Hologic published news for 2024 q4
SEC form 10
2024-11-27 07:24 ET
Hologic published news for 2024 q3
SEC form 10
2024-11-27 00:00 ET
Hologic published news for 2024 q3
SEC form 8
2024-11-04 16:26 ET
Hologic published news for 2024 q3
SEC form 8
2024-11-04 16:26 ET
Hologic published news for 2024 q3
SEC form 10
2024-07-30 16:06 ET
Hologic published news for 2024 q2
SEC form 10
2024-07-30 00:00 ET
Hologic published news for 2024 q2
SEC form 8
2024-07-29 16:01 ET
Hologic published news for 2024 q2
SEC form 8
2024-07-29 16:01 ET
Hologic reported for 2024 q2
SEC form 8
2024-05-03 08:00 ET
Hologic published news for 2024 q1
SEC form 8
2024-05-03 08:00 ET
Hologic published news for 2024 q1
SEC form 10
2024-05-03 07:45 ET
Hologic published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Hologic published news for 2024 q1
SEC form 8
2024-05-02 16:01 ET
Hologic published news for 2024 q1
SEC form 8
2024-05-02 16:01 ET
Hologic reported for 2024 q1
SEC form 10
2024-02-02 00:00 ET
Hologic reported for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Hologic published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Hologic reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Hologic published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Hologic published news for 2023 q4
SEC form 10
2023-11-21 00:00 ET
Hologic published news for 2023 q3
SEC form 8
2023-11-09 16:01 ET
Hologic reported for 2023 q3
SEC form 10
2023-08-01 07:26 ET
Hologic published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Hologic published news for 2023 q2
SEC form 6
2023-07-31 16:01 ET
Hologic reported for 2023 q2
SEC form 8
2023-07-31 00:00 ET
Hologic published news for 2023 q2
SEC form 10
2023-05-02 00:00 ET
Hologic published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Hologic published news for 2023 q1
SEC form 6
2023-03-10 16:15 ET
Hologic published news for 2022 q4
SEC form 6
2023-02-01 16:08 ET
Hologic published news for 2022 q4
SEC form 10
2023-02-01 16:04 ET
Hologic reported for 2022 q4
SEC form 10
2023-02-01 00:00 ET
Hologic reported for 2022 q4
SEC form 8
2023-02-01 00:00 ET
Hologic reported for 2022 q4
SEC form 6
2023-01-19 16:07 ET
Hologic published news for 2022 q4
SEC form 6
2023-01-09 06:00 ET
Hologic published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Hologic published news for 2022 q4
SEC form 6
2022-12-09 16:15 ET
Hologic published news for 2022 q3
SEC form 10
2022-11-15 08:26 ET
Hologic reported for 2022 q3
SEC form 10
2022-11-15 00:00 ET
Hologic reported for 2022 q3
SEC form 6
2022-11-04 16:16 ET
Hologic published news for 2022 q3
SEC form 6
2022-10-31 16:02 ET
Hologic published news for 2022 q3
SEC form 8
2022-10-31 00:00 ET
Hologic reported for 2022 q3
SEC form 6
2022-09-23 16:15 ET
Hologic published news for 2022 q2
SEC form 6
2022-08-30 16:15 ET
Hologic published news for 2022 q2
SEC form 10
2022-07-27 16:06 ET
Hologic reported for 2022 q2
SEC form 6
2022-07-27 16:03 ET
Hologic published news for 2022 q2
SEC form 10
2022-07-27 00:00 ET
Hologic reported for 2022 q2
SEC form 8
2022-07-27 00:00 ET
Hologic reported for 2022 q2
SEC form 10
2022-04-27 16:08 ET
Hologic reported for 2022 q1
SEC form 6
2022-04-27 16:01 ET
Hologic published news for 2022 q1
SEC form 10
2022-04-27 00:00 ET
Hologic reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
Hologic reported for 2022 q1
SEC form 6
2022-03-11 16:07 ET
Hologic published news for 2021 q4
SEC form 10
2022-02-02 16:06 ET
Hologic published news for 2021 q4
SEC form 6
2022-02-02 16:01 ET
Hologic published news for 2021 q4
SEC form 10
2022-02-02 00:00 ET
Hologic published news for 2021 q4
SEC form 8
2022-02-02 00:00 ET
Hologic published news for 2021 q4
SEC form 6
2022-01-20 16:15 ET
Hologic published news for 2021 q4
SEC form 6
2022-01-10 06:00 ET
Hologic published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Hologic published news for 2021 q4
SEC form 10
2021-11-16 08:36 ET
Hologic published news for 2021 q3
SEC form 10
2021-11-16 00:00 ET
Hologic published news for 2021 q3
SEC form 6
2021-11-04 16:02 ET
Hologic published news for 2021 q3
SEC form 6
2021-11-01 16:02 ET
Hologic published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Hologic published news for 2021 q3
SEC form 6
2021-09-27 16:34 ET
Hologic published news for 2021 q2
SEC form 10
2021-07-28 16:13 ET
Hologic published news for 2021 q2
SEC form 6
2021-07-28 16:01 ET
Hologic published news for 2021 q2
SEC form 10
2021-07-28 00:00 ET
Hologic published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Hologic published news for 2021 q2
SEC form 6
2021-06-17 16:30 ET
Hologic published news for 2021 q1
SEC form 10
2021-04-28 16:08 ET
Hologic published news for 2021 q1
SEC form 6
2021-04-28 16:04 ET
Hologic published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
Hologic published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
Hologic published news for 2021 q1
SEC form 6
2021-04-08 17:22 ET
Hologic published news for 2021 q1
SEC form 6
2021-03-12 16:21 ET
Hologic published news for 2020 q4
SEC form 6
2021-01-27 16:26 ET
Hologic published news for 2020 q4
SEC form 10
2021-01-27 16:11 ET
Hologic published news for 2020 q4
SEC form 6
2021-01-21 16:07 ET
Hologic published news for 2020 q4
SEC form 6
2021-01-08 08:30 ET
Hologic published news for 2020 q4
SEC form 10
2020-11-17 08:20 ET
Hologic published news for 2020 q3
SEC form 6
2020-11-06 16:06 ET
Hologic published news for 2020 q3
SEC form 6
2020-11-04 16:01 ET
Hologic published news for 2020 q3
SEC form 6
2020-10-15 16:15 ET
Hologic published news for 2020 q3
SEC form 6
2020-10-06 16:05 ET
Hologic published news for 2020 q3